yingweiwo

Povorcitinib (INCB-54707)

Alias: Povorcitinib; INCB-54707; INCB54707; INCB 54707; 1637677-22-5; Povorcitinib [INN]; N0JWC7RO00; 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide;
Cat No.:V51190 Purity: ≥98%
Povorcitinib is a potent and specific JAK1 inhibitor.
Povorcitinib  (INCB-54707)
Povorcitinib (INCB-54707) Chemical Structure CAS No.: 1637677-22-5
Product category: JAK
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes

Other Forms of Povorcitinib (INCB-54707):

  • Povorcitinib phosphate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Povorcitinib is a potent and specific JAK1 inhibitor. Povorcitinib may be used for studying cutaneous lupus erythematosus (CLE) and carpet lichen (LP) diseases (information disclosed in patent WO2021076124A1).
Biological Activity I Assay Protocols (From Reference)
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C23H22F5N7O
Molecular Weight
507.46
Exact Mass
507.18
CAS #
1637677-22-5
Related CAS #
1637677-22-5;1637677-33-8 (phosphate);
PubChem CID
86280672
Appearance
White to off-white solid powder
LogP
3.1
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
10
Rotatable Bond Count
6
Heavy Atom Count
36
Complexity
860
Defined Atom Stereocenter Count
1
SMILES
C(C1(N2N=CC(C3=C(NN=C3C)C)=C2)CN(C2C=C(F)C(C(=O)N[C@@H](C)C(F)(F)F)=CC=2F)C1)C#N
InChi Key
MSGYSFWCPOBHEV-AWEZNQCLSA-N
InChi Code
InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
Chemical Name
4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide
Synonyms
Povorcitinib; INCB-54707; INCB54707; INCB 54707; 1637677-22-5; Povorcitinib [INN]; N0JWC7RO00; 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ~250 mg/mL (~492.6 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (4.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (4.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.9706 mL 9.8530 mL 19.7060 mL
5 mM 0.3941 mL 1.9706 mL 3.9412 mL
10 mM 0.1971 mL 0.9853 mL 1.9706 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
CTID: NCT07588139
Phase: Phase 1
Status: Recruiting
Date: 2026-06-03
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
CTID: NCT06855498
Phase: Phase 3
Status: Recruiting
Date: 2026-06-01
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
CTID: NCT06516952
Phase: Phase 3
Status: Active, not recruiting
Date: 2026-05-28
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
CTID: NCT07213973
Phase: Phase 2
Status: Recruiting
Date: 2026-05-27
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
CTID: NCT05851443
Phase: Phase 2
Status: Recruiting
Date: 2026-04-14
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
CTID: NCT06516965
Phase: Phase 3
Status: Active, not recruiting
Date: 2026-04-14
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
CTID: NCT06113471
Phase: Phase 3
Status: Active, not recruiting
Date: 2026-03-31
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
CTID: NCT06212999
Phase: Phase 3
Status: Active, not recruiting
Date: 2026-03-23
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
CTID: NCT06113445
Phase: Phase 3
Status: Active, not recruiting
Date: 2026-03-23
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
CTID: NCT05936567
Phase: Phase 2
Status: Completed
Date: 2026-03-12
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
CTID: NCT05620823
Phase: Phase 3
Status: Completed
Date: 2026-02-10
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
CTID: NCT05620836
Phase: Phase 3
Status: Completed
Date: 2026-01-09
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CTID: NCT03607487
Phase: Phase 2
Status: Completed
Date: 2025-08-21
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CTID: NCT04476043
Phase: Phase 2
Status: Completed
Date: 2025-08-12
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
CTID: NCT05624710
Phase: Phase 1
Status: Completed
Date: 2025-08-03
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
CTID: NCT05061693
Phase: Phase 2
Status: Completed
Date: 2025-07-11
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
CTID: NCT06416800
Phase: Phase 1
Status: Completed
Date: 2025-02-06
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
CTID: NCT06505265
Phase: Phase 1
Status: Completed
Date: 2024-09-26
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
CTID: NCT06441318
Phase: Phase 1
Status: Completed
Date: 2024-09-25
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
CTID: NCT06380205
Phase: Phase 1
Status: Completed
Date: 2024-07-03
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
CTID: NCT04818346
Phase: Phase 2
Status: Completed
Date: 2024-04-11
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
CTID: NCT05624723
Phase: Phase 1
Status: Completed
Date: 2024-02-13
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CTID: NCT03569371
Phase: Phase 2
Status: Completed
Date: 2022-09-26
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
CTID: NCT05068466
Phase: Phase 1
Status: Completed
Date: 2022-09-16
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
EudraCT: 2021-006329-23
Phase: Phase 2
Status: Ongoing
Date: 2022-05-05
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
EudraCT: 2020-001981-13
Phase: Phase 2
Status: Completed
Date: 2021-03-02
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety
EudraCT: 2018-000827-15
Phase: Phase 2
Status: Completed
Date: 2018-11-06
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
CTID: jRCT2031240699
Status: Recruiting
Date: 2025-02-21
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
CTID: jRCT2031230185
Status: Recruiting
Date: 2023-06-27
Contact Us